WEC
TBPH icon

Winslow Evans & Crocker’s Theravance Biopharma TBPH Stock Holding History

Winslow Evans & Crocker’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-158
Closed -$1.73K – 1389
2015
Q3 		$1.73K Hold
158
– – ﹤0.01% 1198
2015
Q2 		$2.05K Hold
158
– – ﹤0.01% 1206
2015
Q1 		$2.72K Hold
158
– – ﹤0.01% 1137
2014
Q4 		$2.34K Hold
158
– – ﹤0.01% 1182
2014
Q3 		$3.62K Buy
158
+101
+177% +$2.93K ﹤0.01% 1161
2014
Q2 		$1.82K Buy
+57
New +$1.72K ﹤0.01% 1198

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Winslow Evans & Crocker's TBPH Position: Q4 2015 in Review

Winslow Evans & Crocker sold out of Theravance Biopharma (TBPH) in Q4 2015, closing a stake of 158 shares — an estimated $1.73K sold.

Winslow Evans & Crocker first reported a position in TBPH in Q2 2014 and held it in 6 quarters. The position peaked at $3.62K in Q3 2014. 83 funds tracked by Wall St. Rank hold TBPH as of Q4 2015.

  • Winslow Evans & Crocker reported no remaining Theravance Biopharma position as of Q4 2015 after selling out during the quarter.
  • Winslow Evans & Crocker sold 158 Theravance Biopharma shares in Q4 2015, an estimated $1.73K.
  • Winslow Evans & Crocker first reported a position in Theravance Biopharma in Q2 2014 and held it in 6 quarters.
  • Winslow Evans & Crocker's Theravance Biopharma position peaked at $3.62K in Q3 2014.
  • 83 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2015.

Based on Winslow Evans & Crocker's 13F filing for Q4 2015, filed 27 Jan 2016.